Atossa Therapeutics Inc
ATOS
Company Profile
Business description
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
Contact
1448 NW Market Street
Suite 500
SeattleWA98107
USAT: +1 206 588-0256
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
14
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,858.90 | 13.30 | 0.15% |
| CAC 40 | 8,077.80 | 3.63 | -0.04% |
| DAX 40 | 25,408.64 | 142.11 | 0.56% |
| Dow JONES (US) | 51,828.62 | 478.64 | 0.93% |
| FTSE 100 | 10,695.25 | 15.26 | 0.14% |
| HKSE | 24,616.53 | 106.44 | 0.43% |
| NASDAQ | 27,068.72 | 129.34 | 0.48% |
| Nikkei 225 | 66,403.52 | 39.32 | 0.06% |
| NZX 50 Index | 13,844.56 | 33.45 | 0.24% |
| S&P 500 | 7,743.41 | 39.28 | 0.51% |
| S&P/ASX 200 | 8,686.40 | 21.40 | 0.25% |
| SSE Composite Index | 3,845.51 | 42.86 | -1.10% |